Raymond James Upgrades ProQR Therapeutics to Strong Buy, Raises Price Target to $14
Benzinga Newsdesk 2 years ago
NewsUpgradesPrice TargetAnalyst Ratings
Raymond James analyst Steven Seedhouse upgrades ProQR Therapeutics (NASDAQ:PRQR) from Outperform to Strong Buy and raises the price target from $6 to $14.
Raymond James analyst Steven Seedhouse upgrades ProQR Therapeutics (NASDAQ:PRQR) from Outperform to Strong Buy and raises the price target from $6 to $14.